Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | HMGCR | P04035 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.40 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL29108824 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL17511198 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL17511202 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL28219134 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL27872788 | 0.94 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL9805785 | 0.92 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL27621753 | 0.92 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL9805787 | 0.92 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL15660063 | 0.92 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL6838001 | 0.92 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024198046-A1 | BIOMARKER AND SYSTEM FOR PREDICTING EVOLUTION INTO ACLF OR DEATH OF ACLF PATIENT, AND USES THEREOF | 上海甘宁医疗科技有限公司 | 2024-10-03 | — | — | WO | claimed |
| CN-115947365-A | Cerium trifluoride nano material for experiments and preparation method thereof | 池州学院 | 2023-04-11 | — | — | CN | claimed |
| CN-103797013-A | Pyrazolo [3,4-d ] pyrimidine compounds, their preparation and use as sigma ligands | ESTEVE LABOR DR | 2014-05-14 | — | — | CN | claimed |
| CN-103464173-A | Preparation method of cadmium sulfide/ferroferric oxide composite material | UNIV LIAOCHENG | 2013-12-25 | — | — | CN | claimed |
| US-4401439-A | CITRATE SALT OF AN N-CARBAMOYL PIPERAZINE COMPOUND AS A FUEL ADDITVE | SHELL OIL COMPANY (US) | 1983-08-30 | — | — | US | claimed |
| CN-119505870-A | Environment-responsive charge conversion carbon quantum dot and preparation method and application thereof | 汤镇榕 | 2025-02-25 | — | — | CN | disclosed |
| CN-119419246-A | Novel material with extremely durable lithium intercalation and method for producing same | 14集团技术公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240415117-A1 | MECHANISM OF UREA/SOLID ACID INTERACTION UNDER STORAGE CONDITIONS AND STORAGE STABLE SOLID COMPOSITIONS COMPRISING UREA AND ACID | ECOLAB USA INC. | 2024-12-19 | — | — | US | disclosed |
| US-12096769-B2 | Mechanism of urea/solid acid interaction under storage conditions and storage stable solid compositions comprising urea and acid | ECOLAB USA INC. (US) | 2024-09-24 | — | — | US | disclosed |
| CN-113347884-B | Citrate perhydrate and use thereof | 百莱姆工程有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-117625172-A | Silane carbon dot/crystal hybrid material and preparation method and application thereof | 中国科学院理化技术研究所 | 2024-03-01 | — | — | CN | disclosed |
| EP-4043541-B1 | MECHANISM OF UREA/SOLID ACID INTERACTION UNDER STORAGE CONDITIONS AND METHOD OF MAKING STORAGE STABLE SOLID COMPOSITIONS COMPRISING UREA AND ACID | ECOLAB USA INC (US) | 2024-02-21 | — | — | EP | disclosed |
| US-6152099-A | Apparatus and method of supplying additive to internal combustion engine | URICH CARL L (US) | 2000-11-28 | — | — | US | disclosed |
| US-5986070-A | NERVE GROWTH FACTOR EXPRESSED IN PROKAYOTIC CELLS WITH PROTEINS | AMGEN INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0450386-B1 | Production of biologically active, recombinant members of the NGF/BDNF family of neurotrophic proteins | AMGEN INC (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0610955-B1 | Quaternized aminomethyl acrylamide polymermicroemulsions, methods of producing and use of same | CYTEC TECH CORP (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0610955-A2 | Quaternized aminomethyl acrylamide polymermicroemulsions, methods of producing and use of same | CYTEC TECHNOLOGY CORP. (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5320783-A | Detergent gels containing ethoxylated alkyl sulfate surfactants in hexagonal liquid crystal form | THE PROCTER & GAMBLE COMPANY (US) | 1994-06-14 | — | — | US | disclosed |
| EP-0450386-A2 | Production of biologically active, recombinant members of the NGF/BDNF family of neurotrophic proteins | SYNERGEN, INC. (US) | 1991-10-09 | — | — | EP | disclosed |
| US-4401439-A | CITRATE SALT OF AN N-CARBAMOYL PIPERAZINE COMPOUND AS A FUEL ADDITVE | SHELL OIL COMPANY (US) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415117-A1 | MECHANISM OF UREA/SOLID ACID INTERACTION UNDER STORAGE CONDITIONS AND STORAGE STABLE SOLID COMPOSITIONS COMPRISING UREA AND ACID | SLC14A1, USP25, USP14 | MEN1 4047/4885ALDH1A1 1868/4885HMGCR 4737/4885 |
| US-12096769-B2 | Mechanism of urea/solid acid interaction under storage conditions and storage stable solid compositions comprising urea and acid | SLC14A1, USP25, USP14 | MEN1 4047/4885ALDH1A1 1868/4885HMGCR 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.